Difference between revisions of "Dabigatran (Pradaxa)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| + | Also known as Pradax or Prazaxa. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.<ref name="insert">[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Dabigatran (Pradaxa) package insert]</ref><ref>[ | + | Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.<ref name="insert">[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Dabigatran (Pradaxa) package insert]</ref><ref>[[Media:Dabigatran.pdf | Dabigatran (Pradaxa) package insert (locally hosted backup)]]</ref><ref>[http://www.pradaxa.com Pradaxa manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 7: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf#page=11 Dabigatran (Pradaxa) package insert pages 11-15]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Hematology medications]] | ||
| + | [[Category:Hemostasis medications]] | ||
| + | [[Category:Direct thrombin inhibitors]] | ||
Revision as of 05:21, 14 October 2012
Also known as Pradax or Prazaxa.
General information
Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Dabigatran (Pradaxa) package insert pages 11-15[1]
- Dabigatran (Pradaxa) patient drug information (UpToDate)[4]